U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Postmarket Drug Safety Information for Patients and Providers
  5. Darunavir Ethalolate (marketed as Prezista) Information
  1. Drug Safety and Availability

Darunavir Ethalolate (marketed as Prezista) Information

Darunavir Ethalolate (marketed as Prezista) Information

Prezista is a human immunodeficiency virus (HIV-1) protease inhibitor indicated for the treatment of HIV-1 infection in adult patients. Prezista is also indicated for the treatment of HIV-1 infection in pediatric patients 3 years of age and older. Prezista must be co-administered with ritonavir (Prezista/ritonavir) and with other antiretroviral agents.

Adverse reactions or quality problems experienced with the use of this Product may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.

Related Information

Regulatory History and Labeling from Drugs@FDA